Our cholesterol labeling of oligonucleotides service provides custom design, synthesis, conjugation, purification, and analytical support for DNA, RNA, siRNA, antisense oligonucleotides, aptamers, and other research-use nucleic acid constructs. Covalent attachment of cholesterol adds a strong hydrophobic domain to an otherwise highly polar oligonucleotide, enabling researchers to investigate membrane association, cellular uptake, lipoprotein interactions, vesicle anchoring, self-assembly, and delivery behavior. Successful construct design depends on more than adding a sterol group: attachment position, linker length, strand orientation, backbone chemistry, sequence composition, and purification strategy can all influence handling and experimental performance.
We integrate cholesterol-modification planning with custom oligonucleotide synthesis, fit-for-purpose conjugation chemistry, hydrophobicity-aware purification, and analytical verification. Projects can be configured around standard 3'- or 5'-cholesterol-TEG formats, alternative spacers, cleavable linkers, internal attachment concepts, duplex constructs, or customer-supplied cholesterol derivatives. Our goal is to deliver a clearly defined cholesterol-modified oligonucleotide with the documentation and handling guidance needed for efficient downstream research.
Fig 1. Structure of cholesterol-conjugated antisense oligonucleotides. (Wada et al., 2016)
Attachment Position Selection: A 3', 5', or selected internal attachment can change how the cholesterol group is presented relative to the nucleic acid sequence. We review target function, strand orientation, terminal requirements, and assay geometry before recommending a labeling position.
Hydrophobicity and Solubility: Cholesterol can promote membrane interaction, but it can also increase retention, adsorption, aggregation, and reconstitution difficulty. Spacer architecture, oligonucleotide composition, counterion, concentration, and buffer conditions are considered together to improve practical handling.
Linker-Dependent Performance: Direct attachment may place the sterol too close to the oligonucleotide, while an unsuitable spacer can add unnecessary flexibility or interfere with the intended construct geometry. TEG, alkyl, PEG-like, and cleavable linkers can be evaluated according to project needs.
Purification of Hydrophobic Conjugates: Cholesterol-modified oligonucleotides often require separation methods that distinguish the desired conjugate from unconjugated oligonucleotide, truncated sequences, and coupling-related impurities. We develop purification plans around construct hydrophobicity, length, scale, and required purity.
Duplex and Formulation Compatibility: For siRNA and other duplex formats, cholesterol placement must be coordinated with strand function, annealing, and downstream handling. Our lipid-oligonucleotide conjugation capabilities support strand-specific planning and research-oriented formulation decisions.
Our service model supports both routine cholesterol-TEG oligonucleotides and nonstandard sterol-conjugate projects. The scope can begin with a sequence and application brief or with a fully specified construct requiring synthesis, conjugation, purification, and release testing.
Each project is reviewed for chemical feasibility, terminal functionality, linker placement, backbone compatibility, duplex orientation, and expected handling behavior. This coordinated approach helps research teams avoid fragmented outsourcing and reduces the risk of receiving a structurally correct but impractical conjugate.
The most suitable labeling format depends on where the cholesterol must be presented, whether a terminal group must remain available, how the construct will be purified, and whether the oligonucleotide is used as a single strand or part of a duplex. The table below summarizes common design routes and their practical selection factors.
| Design Format | Attachment Strategy | Typical Research Fit | Key Decision Factors | Service Considerations |
| 3' Cholesterol-TEG | Cholesterol-bearing solid support with a TEG spacer | Uptake studies, membrane association, terminal blocking, duplex constructs | Need for free 5' end, strand orientation, spacer length, sequence chemistry | Efficient terminal definition; purification must address increased hydrophobicity |
| 5' Cholesterol-TEG | Cholesterol phosphoramidite or compatible post-synthesis coupling | Uptake comparison, surface presentation, membrane anchoring, selected duplex designs | Need for free 3' end, terminal accessibility, coupling efficiency, downstream geometry | Supports direct 5' presentation; route depends on oligo chemistry and scale |
| Direct Terminal Cholesterol | Shorter spacer or direct sterol-linked terminal architecture | Compact constructs and studies focused on close sterol presentation | Solubility, steric effects, membrane insertion, analytical behavior | Requires careful feasibility review and handling assessment |
| Internal Cholesterol | Compatible internal phosphoramidite or handle-directed conjugation | Defined display geometry, multicomponent probes, nanostructure assembly | Hybridization tolerance, folding, steric burden, positional accessibility | Custom route and analytical planning are usually required |
| Cleavable Cholesterol | Cholesterol attached through a disulfide or another stimulus-responsive linker | Mechanistic release studies and comparison of retained versus releasable sterol | Cleavage conditions, linker stability, assay matrix, storage environment | Linker chemistry must be matched to synthesis, purification, and study conditions |
| Strand-Specific Duplex | Cholesterol installed on one selected strand before duplex formation | siRNA, heteroduplex, and paired-strand uptake or localization studies | Guide/passenger assignment, terminal requirements, annealing, strand purity | Individual-strand QC and optional duplex preparation can be included |
Cholesterol labeling changes chromatographic retention, sample recovery, and handling behavior. A fit-for-purpose analytical package should confirm that the intended conjugate was formed, that major unconjugated or truncated components were removed, and that the final material can be used reproducibly in the planned research workflow.
| Quality Attribute | Why It Matters | Typical Approach | Common Risk | Possible Deliverable |
| Conjugate Identity | Confirms the expected oligonucleotide and cholesterol-containing construct | LC-MS, MALDI-TOF MS, or another mass-based method as appropriate | Adducts, broad envelopes, or limited ionization for complex hydrophobic constructs | Observed mass summary and identity assessment |
| Purity Profile | Estimates the proportion of desired conjugate relative to major impurities | Analytical RP-HPLC or another suitable chromatographic method | Co-elution of related species or strong surface retention | Chromatogram and reported purity value |
| Conjugation Completion | Distinguishes cholesterol-labeled material from unconjugated oligonucleotide | Comparative chromatography supported by mass analysis | Residual starting oligonucleotide or partially modified material | Conjugation-status review |
| Concentration | Supports accurate dosing, annealing, and assay setup | UV absorbance with sequence-based calculation and project-specific correction | Adsorption, incomplete dissolution, or uncertainty from non-oligo components | Amount, concentration, and reconstitution information |
| Duplex Readiness | Helps confirm that labeled and complementary strands can be prepared for paired use | Molar-ratio review, controlled annealing, and optional duplex-focused analysis | Incomplete annealing, strand imbalance, or hydrophobic aggregation | Annealing record or duplex preparation note |
| Handling Behavior | Reduces loss during reconstitution, transfer, storage, and assay preparation | Solubility observation, buffer screening, and concentration-dependent handling review | Precipitation, adsorption, slow dissolution, or variable recovery | Storage and handling recommendations |
The workflow is designed to align chemistry decisions with the intended research use before synthesis begins. Each stage defines the construct, controls hydrophobicity-related risks, and creates clear checkpoints for technical review and material acceptance.
We collect the oligonucleotide sequence, molecule type, backbone and sugar modifications, requested scale, purity target, attachment preference, and downstream research objective. This establishes whether a standard cholesterol-TEG format or a custom conjugation route is appropriate.
The team evaluates 3', 5', or internal placement together with linker length, strand orientation, terminal functionality, and expected solubility. Key tradeoffs are documented so the selected design is technically defensible.
We define the synthesis or post-synthesis conjugation route, purification approach, analytical package, delivery form, and acceptance criteria. Customer-supplied sterol derivatives or linkers are reviewed before material transfer.
The oligonucleotide is synthesized with the agreed sequence and modifications, followed by direct cholesterol incorporation or handle-directed conjugation. Process conditions are adjusted for sequence complexity, chemistry, scale, and hydrophobic conjugate behavior.
The crude material is purified using a method selected for the conjugate profile. Identity, purity, amount, and other agreed attributes are assessed, and duplex preparation or handling checks are completed when included in scope.
Final material is supplied in the agreed form with project documentation, reconstitution guidance, and storage recommendations. Post-delivery support addresses handling, experimental setup, and options for follow-on linker or position comparisons.
Cholesterol modification combines nucleic acid chemistry with hydrophobic conjugate design. Our service emphasizes construct-level decision support, practical purification, and transparent analytical planning rather than treating cholesterol as a simple catalog end label.
Cholesterol-labeled oligonucleotides are used when a nucleic acid requires a covalently attached hydrophobic handle. The modification can support controlled comparison of uptake, membrane interaction, assembly, localization, and chromatographic behavior across a range of research platforms.
Whether your project requires a routine 3' cholesterol-TEG oligonucleotide, a 5'-labeled RNA strand, a position-and-linker comparison panel, a cleavable sterol conjugate, or a custom cholesterol derivative, our team can help define a practical route from sequence review to purified material. Share the sequence, oligonucleotide type, desired attachment site, scale, purity expectation, and intended research use so we can recommend an appropriate design, purification strategy, and analytical package. Contact us to request a technical assessment and project quotation.
Cholesterol enhances cellular uptake by increasing lipophilicity and membrane permeability. This modification significantly improves delivery efficiency and intracellular stability.
We primarily modify the 5' end to minimize interference with hybridization. 3' end modifications are also available for specific application needs.
We employ RP-HPLC and gel filtration chromatography for optimal separation. These techniques effectively resolve modified and unmodified oligo species.
Loading ......
